Clinical Trials Logo

Clinical Trial Summary

Sarcoidosis is a granulomatous disease for which the molecular and immunologic association with mycobacteria continues to strengthen. The investigators are interested in conducting a proof-of-concept investigation of the effects of antibiotics on sarcoidosis resolution. The investigators hypothesize that pulmonary sarcoidosis will improve faster if patients are given antimycobacterial therapy, in addition to their standard therapy.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01169038
Study type Interventional
Source Vanderbilt University
Contact
Status Completed
Phase Phase 1
Start date July 2010
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT04064242 - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Phase 2
Terminated NCT00262132 - Mycophenolate for Pulmonary Sarcoidosis Phase 3
Recruiting NCT05415137 - Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Phase 3
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT04318392 - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting NCT03755245 - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis N/A
Completed NCT01587001 - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis N/A
Recruiting NCT05890729 - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 1/Phase 2
Recruiting NCT02824419 - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Phase 2/Phase 3
Recruiting NCT06205121 - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis Phase 2
Completed NCT02200146 - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Phase 3
Terminated NCT01732211 - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Phase 2
Enrolling by invitation NCT06169397 - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2
Active, not recruiting NCT05368883 - Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis N/A
Not yet recruiting NCT05247554 - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Phase 3
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting NCT02188017 - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Phase 4
Recruiting NCT06113991 - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed NCT00701207 - Study of Nicotine Patches in Patients With Sarcoidosis Early Phase 1
Completed NCT03824392 - Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Phase 1/Phase 2